A Developing Novel Bio-synthetic Peptide CompanyAHBLab is the Taiwan biotech company focusing on developing and supplying novel bio-synthetic peptides and their commercialized products with self-developed core technology "bio-synthetic peptidomimetic platform (GRPP). " GRPP" is completed in the mass production process for tetrapeptides to henicosapeptide with low-cost and high-yield methods, aiming at peptide-based therapy relevant to cosmetics, nutriceutical, and medicine. At present, 10 bio-synthetic peptide materials and 4 bio-synthetic peptide-based series of products have been completed. The bio-synthetic peptides for the treatment of degenerative arthritis, and its medical application has obtained 6 international invention patents from Taiwan, Japan, and China, The other broad patent portfolio of 18 patent applications cover 6 key markets.
AHBLab Does Global Business
Sales of Bulks, materials, Customized products, PL brand
wholesales and retails
Patent licensing, Strategic alliance, Partnership, Franchise
OEM/ODM
Bio-synthetic Peptide-Based Therapy
AHBLab specializes in developing bio-synthetic peptide materials for oral, transdermal, and sublingual absorption and conducts its research on the prevention and treatment of diseases.
Bio-synthetic Peptide Application
The applications of bio-synthetic peptides that have completed mass production include degenerative arthritis, tendon fasciitis, ligamentitis, excretion of lactic acid and blood stasis, anti-gingival recession, oral and gingival anti-inflammation, repair oral popi and wound, proliferating oral mucosa to prevent oral cancer, stimulate the proliferation of gum tissue, protect and proliferate the oral mucosa, anti-wrinkle, anti-osteoporosis, anti-stress, sleep disorder, antidepressant, treating diabetes, anti-inflammatory and analgesic (replacing NSAID, steroids, and cytokine monoclonal antibodies), quickly reduce CRP index(autoimmune diseases such as rheumatoid arthritis, etc.), increase blood oxygen saturation,
enhance immunity, and treat cancer and metastatic cancer.